A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects

被引:93
作者
Cate, Thomas R.
Rayford, Yolanda
Nino, Diane
Winokur, Patricia [2 ]
Brady, Rebecca [3 ]
Belshe, Robert [4 ]
Chen, Wilbur [5 ]
Atmar, Robert L.
Couch, Robert B. [1 ]
机构
[1] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA
[2] Carver Coll Med, Iowa City, IA 52242 USA
[3] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA
[4] St Louis Univ, Sch Med, Dept Internal Med, Div Infect Dis,Edward A Doisy Res Ctr, St Louis, MO 63104 USA
[5] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
关键词
Influenza vaccine; Neuraminidase; Antibody; VIRUS-VACCINE; IMMUNITY; HEMAGGLUTININ;
D O I
10.1016/j.vaccine.2009.12.041
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antibody to the neuraminidase (NA) antigen of influenza viruses has been shown to correlate with immunity to influenza in humans and animal models. In a previous report, we showed that an inactivated influenza vaccine containing 60 mu g of the hemagglutinin (HA) of each strain induced significantly more serum anti-HA antibody among elderly persons than did the standard vaccine containing 15 mu g of the HA of each component. We developed a lectin-based assay for anti-NA antibody and used it to measure anti-NA antibody responses among subjects who had participated in that study. The high dosage vaccine contained eight times as much NA activity as the standard vaccine and induced a significantly higher frequency of antibody responses and higher mean postvaccination anti-NA titers to the N1 and N2 of the A/H1N1 and A/H3N2 viruses in the vaccines than did the standard vaccine. Ensuring an increased antibody response to the NA antigen in inactivated influenza virus vaccines should increase the protection against influenza. An increased quantity of the NA antigen in the vaccine will ensure an increased response. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2076 / 2079
页数:4
相关论文
共 20 条
[1]  
Couch R B, 2003, Dev Biol (Basel), V115, P25
[2]   INDUCTION OF PARTIAL IMMUNITY TO INFLUENZA BY A NEURAMINIDASE-SPECIFIC VACCINE [J].
COUCH, RB ;
KASEL, JA ;
GERIN, JL ;
SCHULMAN, JL ;
KILBOURNE, ED .
JOURNAL OF INFECTIOUS DISEASES, 1974, 129 (04) :411-420
[3]  
COUCH RB, 1984, MOL VIROLOGY EPIDEMI, P119
[4]   Seasonal inactivated influenza virus vaccines [J].
Couch, Robert B. .
VACCINE, 2008, 26 :D5-D9
[5]   Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects [J].
Couch, Robert B. ;
Winokur, Patricia ;
Brady, Rebecca ;
Belshe, Robert ;
Chen, Wilbur H. ;
Cate, Thomas R. ;
Sigurdardottir, Bryndis ;
Hoeper, Amy ;
Graham, Irene L. ;
Edelman, Robert ;
He, Fenhua ;
Nino, Diane ;
Capellan, Jose ;
Ruben, Frederick L. .
VACCINE, 2007, 25 (44) :7656-7663
[6]   PURIFIED INFLUENZA-VIRUS HEMAGGLUTININ AND NEURAMINIDASE ARE EQUIVALENT IN STIMULATION OF ANTIBODY-RESPONSE BUT INDUCE CONTRASTING TYPES OF IMMUNITY TO INFECTION [J].
JOHANSSON, BE ;
BUCHER, DJ ;
KILBOURNE, ED .
JOURNAL OF VIROLOGY, 1989, 63 (03) :1239-1246
[7]  
Kilbourne E.D., 1987, INFLUENZA
[8]   ANTIVIRAL ACTIVITY OF ANTISERUM SPECIFIC FOR AN INFLUENZA VIRUS NEURAMINIDASE [J].
KILBOURNE, ED ;
LAVER, WG ;
SCHULMAN, JL ;
WEBSTER, RG .
JOURNAL OF VIROLOGY, 1968, 2 (04) :281-+
[9]   Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans [J].
Kilbourne, ED ;
Couch, RB ;
Kasel, JA ;
Keitel, WA ;
Cate, TR ;
Quarles, JH ;
Grajower, B ;
Pokorny, BA ;
Johansson, BE .
VACCINE, 1995, 13 (18) :1799-1803
[10]   INDEPENDENT AND DISPARATE EVOLUTION IN NATURE OF INFLUENZA-A VIRUS HEMAGGLUTININ AND NEURAMINIDASE GLYCOPROTEINS [J].
KILBOURNE, ED ;
JOHANSSON, BE ;
GRAJOWER, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (02) :786-790